Hims & Hers Health, Inc. $HIMS Shares Purchased by Candriam S.C.A.

Candriam S.C.A. boosted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 245.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 306,273 shares of the company’s stock after buying an additional 217,493 shares during the period. Candriam S.C.A. owned approximately 0.14% of Hims & Hers Health worth $17,372,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of HIMS. Quent Capital LLC acquired a new stake in shares of Hims & Hers Health in the third quarter worth $28,000. Virtus Advisers LLC purchased a new stake in Hims & Hers Health during the 2nd quarter worth $26,000. Quaker Wealth Management LLC acquired a new stake in Hims & Hers Health in the 2nd quarter valued at $29,000. Bessemer Group Inc. increased its holdings in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after purchasing an additional 312 shares in the last quarter. Finally, Hilltop National Bank purchased a new position in Hims & Hers Health in the third quarter valued at about $35,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HIMS has been the subject of several analyst reports. Zacks Research downgraded Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. BTIG Research reduced their price target on Hims & Hers Health from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. KeyCorp initiated coverage on Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating for the company. Citigroup dropped their price objective on shares of Hims & Hers Health from $30.00 to $16.50 and set a “sell” rating on the stock in a research note on Monday. Finally, Evercore started coverage on shares of Hims & Hers Health in a research report on Monday, January 12th. They set an “in-line” rating and a $33.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average price target of $39.96.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: HIMS halted the compounded semaglutide pill after the FDA and industry pushback, a move management says follows “constructive conversations” that may reduce immediate regulatory exposure. Hims & Hers is scrapping its plan for a knockoff pill
• Neutral Sentiment: Some analysts/commentators argue the market has overreacted because HIMS’ business is broader than GLP-1s (weight-loss revenue estimated at ~30% of 2025), suggesting potential buying opportunities if fundamentals hold. Seeking Alpha: Don’t Fall For The Hysteria
• Neutral Sentiment: Some market commentators call the sharp drop a “buy-the-dip” setup for longer-term investors if regulatory/legal risks stabilize. HIMS 22% Collapse Looks Like A ‘Buy The Dip’ Moment
• Negative Sentiment: Novo Nordisk filed a U.S. patent lawsuit alleging HIMS infringed patents on semaglutide products, seeking to block sales and recover damages — a direct legal threat to HIMS’ ability to re-enter this market. Reuters: Novo Nordisk opens new front with patent suit
• Negative Sentiment: The FDA signaled it will restrict access to active ingredients used to compound GLP‑1s, increasing regulatory enforcement risk for firms offering copycat products. CNBC: Novo Nordisk sues Hims & Hers
• Negative Sentiment: Analysts cut price targets and ratings (Citigroup to $16.50 sell; TD Cowen and BofA also lowered targets/ratings), reflecting weaker near-term forecasts and increasing downside risk. Benzinga: Analyst cuts
• Negative Sentiment: An investor fraud/derivative investigation invitation has been announced, adding potential legal/financial overhang. BusinessWire: Fraud investigation notice
• Negative Sentiment: Share price volatility and a move to 52‑week lows reflect investor concern over execution, management decisions and dependency on GLP‑1 related revenue. Fool: Hims drops on lawsuit and regulatory risk

Hims & Hers Health Trading Down 16.0%

Shares of HIMS opened at $19.33 on Tuesday. Hims & Hers Health, Inc. has a one year low of $16.35 and a one year high of $72.98. The stock has a 50-day moving average price of $32.60 and a 200 day moving average price of $43.05. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The company has a market capitalization of $4.40 billion, a P/E ratio of 35.80, a P/E/G ratio of 3.79 and a beta of 2.43.

Hims & Hers Health declared that its Board of Directors has approved a stock repurchase program on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In other news, insider Patrick Harrison Carroll sold 10,021 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $367,870.91. Following the sale, the insider owned 169,940 shares in the company, valued at approximately $6,238,497.40. This represents a 5.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the transaction, the insider owned 6,175 shares of the company’s stock, valued at $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 129,337 shares of company stock worth $4,651,648 over the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.